Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?

KRAS and BRAF mutations lead to the constitutive activation of EGFR signaling through the oncogenic Ras/Raf/Mek/Erk pathway. Currently, KRAS is the only potential biomarker for predicting the efficacy of anti-EGFR monoclonal antibodies (mAb) in colorectal cancer (CRC). However, a recent report sugge...

Descripción completa

Detalles Bibliográficos
Autor principal: Yokota, Tomoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343383/
https://www.ncbi.nlm.nih.gov/pubmed/22043994
http://dx.doi.org/10.2174/187152012799014968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343383/
https://www.ncbi.nlm.nih.gov/pubmed/22043994
http://dx.doi.org/10.2174/187152012799014968

Ejemplares similares